Ref ID: 19418
Author:
M. O. Popova,1 A. G. Volkova,1 V. Vavilov,1 S. N. Bondarenko,1
M. Y. Averjanova,1 N. V. Stancheva,1 O. V. Paina,1 E. V.
Morozova,1 S. N. Shiryaev,1 A. Gevorgyn,1 I. S. Zyuzgin,2 Y. V.
Borzova,3 S. N. Khostelidi,3 T. S. Bogomolova,3 L. S.
Zubarovs
Author address:
1I.Pavlov State Madical University, St.Petersburg, Russian
Federation; 2Leningrad Region Clinical Hospital, St.Petersburg,
Russian Federation and 3Department of Clinical Mycology, I.
Mechnikov Nord-Western State Medical University, St.Petersburg,
Full conference title:
6th Trends in Medical Mycology 2013
Date: 11 October 2014
Abstract:
Background In recent years mucormycosis (M) has become an
important cause of morbidity and mortality in allogeneic hematopoi-
etic stem cell transplant (allo-HSCT) recipients. This study focuses on
etiology, clinical forms and outcome of M and factors which influ-
ences on overall survival (OS) in allo-HSCT recipients.
Methods 14 pts with M after allo-HSCT were included in 2009-
2013 yy. Baseline patient characteristics and treatment are outlined
in Table 1. EORTC/MSG 2008 diagnostic criteria of proven and prob-
able invasive fungal disease (IFD) were used.
Results Incidence of M was 2,4% (14/582, allo-HSCT 2009-2012).
There were 6 proven (43%) and 8 probable (57%) cases of M in 14 pts
with predominantly acute leukemia (71%). Median date of M onset
after allo-HSCT was D + 105 (14-449). One case of M was diagnosed
post-mortally. Main clinical forms of M were pulmonary 79%, rhinoce-
rebral 7%, subcutaneous/osteomyelitis 7%, and bowel 7%. In 79% pts
bronchoscopy was performed, in 100% cases it was informative for the
diagnosis. In 57% of cases diagnosis was confirmed by culture. Etio-
logic agents of M were Rhizopus spp. (75%), Rhizomucor spp. (12.5%),
Mucor spp. (12.5%), and L. corymbifera (12.5%). In 50% cases M was
diagnosed after or with invasive aspergillosis (IA). 12-week OS after
diagnosis of M was 31%, 6-months OS in – 31%, and 1-year OS – 23%.
Abstract Number: p182
Conference Year: 2013
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a